Concerning the targeting of glutamine metabolism, there is one ongoing clinical trial testing the inhibition of glutaminase (GLS), the first enzyme involved in glutaminolysis, in combination with chemotherapy plus anti-PD1 for the treatment of non-small cell lung cancer. This evidence concerns the gene GLS and non-small cell lung carcinoma.